Cargando…

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors

BACKGROUND: Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain capable of activating T-cells. CARs displayed on the surface of transduced cells perform non-MHC-restricted antigen recognition and activating...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Oliveira, Satiro N, Wang, Jiexin, Ryan, Christine, Morrison, Sherie L, Kohn, Donald B, Hollis, Roger P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Methodology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623748/ https://www.ncbi.nlm.nih.gov/pubmed/23360526 http://dx.doi.org/10.1186/1479-5876-11-23

Ejemplares similares

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
por: Qin, Haiying, et al.
Publicado: (2018)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
por: Rataj, Felicitas, et al.
Publicado: (2018)

Fully human CD19-specific chimeric antigen receptors for T-cell therapy
por: Sommermeyer, Daniel, et al.
Publicado: (2017)

Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis
por: Bin dokhi, Haifa, et al.
Publicado: (2022)

Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
por: Dixon, Brianne N., et al.
Publicado: (2020)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
por: Gu, Runxia, et al.
Publicado: (2020)

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
por: Mihara, Keichiro, et al.
Publicado: (2017)

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
por: Morita, Daisuke, et al.
Publicado: (2017)

Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
por: Li, Sujun, et al.
Publicado: (2019)

Apoptosis of CD19(+) chimeric antigen receptor T cells after treatment with chemotherapeutic agents
por: Yi, Wenfang, et al.
Publicado: (2018)

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia
por: Delgado, Julio, et al.
Publicado: (2019)

2708. Infectious Complications Among CD19 Chimeric Antigen Receptor T-cell Recipients
por: Huggins, Jonathan, et al.
Publicado: (2023)

CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity
por: Haque, Shabirul, et al.
Publicado: (2021)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies
por: Luanpitpong, Sudjit, et al.
Publicado: (2021)

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

CD24Fc: an emerging COVID-19 therapy
por: Eckhardt, Christina M, et al.
Publicado: (2022)

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
por: Mancikova, Veronika, et al.
Publicado: (2020)

Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series
por: Dhaliwal, Armaan, et al.
Publicado: (2023)

Journal Club: Anti‐CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus
por: Boulougoura, Afroditi, et al.
Publicado: (2023)

Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells
por: An, Na, et al.
Publicado: (2016)

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
por: Ying, Zhitao, et al.
Publicado: (2021)

Case report: Hashimoto’s thyroiditis after CD19 chimeric antigen receptor T-cell therapy
por: Chen, Panpan, et al.
Publicado: (2022)

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
por: Tseng, Hsiang-chi, et al.
Publicado: (2020)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry
por: Zheng, Zhili, et al.
Publicado: (2012)

Evaluation of Nonviral piggyBac and lentiviral Vector in Functions of CD19chimeric Antigen Receptor T Cells and Their Antitumor Activity for CD19(+) Tumor Cells
por: Lin, Zhicai, et al.
Publicado: (2022)

Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct
por: Jimenez, Anne-Sophie, et al.
Publicado: (2011)

CD8(+) chimeric antigen receptor T cells manufactured in absence of CD4(+) cells exhibit hypofunctional phenotype
por: Lee, Sang Yun, et al.
Publicado: (2023)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2017)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
por: Burns, Ethan A., et al.
Publicado: (2021)

Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions
por: Chavez, Julio C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9kd1jj4khj2veeshn46q5k1gmp